You are here

  • Home
  • Archive
  • Volume 30, Issue Suppl 3
  • 3 Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations

Citation Tools

Article menu

Download PDFPDF

Oral Plenary
Plenary I
IGCS20_1268
3 Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Weberpals J, Oza A, Lorusso D, et al
3 Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations
International Journal of Gynecologic Cancer 2020;30:A2-A3.